REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is a clinical-stage biopharmaceutical company focused on central nervous system and neuropsychiatric drug development, including candidates targeting schizophrenia and related disorders. The company reached public markets through a SPAC transaction and filed its annual Form 10-K with the SEC on May 4, 2020. Operating in the healthcare and biopharmaceutical sector, RVPH continues to advance its CNS pipeline as a post-combination listed entity. The 10-K, carrying accession number 0001104659-20-055760, represents the company's formal annual disclosure under the RVPH ticker on Nasdaq. For full deal data, filing history, and peer analytics on Reviva and comparable SPAC-derived healthcare issuers, sign up for complete access at SpacDesk.